Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment

AstraZeneca

Status: Completed

Conditions: Schizophrenia

Study type: Observational

Funder types: Industry

Identifiers

NCT00758251

NIS-NLV-SER-2008/1

Details and patient eligibility

About

The purpose of this study is to assess severity of illness in schizophrenia patients in routine clinical practice at the time of entry in the study and after the treatment with Seroquel XR for 8 weeks.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients with Schizophrenia prescribed on Seroquel XR according to the approved product information before inclusion in this non-interventional study
• Signed and dated Patient Informed Consent (ICF)

Exclusion criteria

• Hypersensitivity to the active substance or to any of the excipients of Seroquel XR

Trial design

80 participants in 1 patient group

1

Description:

Adult schizophrenia patients already on Seroquel XR therapy